S&P 500   3,970.99
DOW   32,237.53
QQQ   310.89
Ukraine demands emergency UN meeting over Putin nuclear plan
Modern Day Options Trading For Beginners! (Ad)pixel
Factory or farm? Oregon may alter land use for chipmakers
Travel disruption hits Germany on eve of transport strike
My No. 1 dividend stock for a LIFETIME of income. (Ad)
Adele extends Las Vegas residency, plans concert film
Berlin climate proposal fails to get enough yes votes to win
My No. 1 dividend stock for a LIFETIME of income. (Ad)
Turkmenistan votes for new, opposition-free parliament
Technical issues at Lufthansa cause delays in Frankfurt
S&P 500   3,970.99
DOW   32,237.53
QQQ   310.89
Ukraine demands emergency UN meeting over Putin nuclear plan
Modern Day Options Trading For Beginners! (Ad)pixel
Factory or farm? Oregon may alter land use for chipmakers
Travel disruption hits Germany on eve of transport strike
My No. 1 dividend stock for a LIFETIME of income. (Ad)
Adele extends Las Vegas residency, plans concert film
Berlin climate proposal fails to get enough yes votes to win
My No. 1 dividend stock for a LIFETIME of income. (Ad)
Turkmenistan votes for new, opposition-free parliament
Technical issues at Lufthansa cause delays in Frankfurt
S&P 500   3,970.99
DOW   32,237.53
QQQ   310.89
Ukraine demands emergency UN meeting over Putin nuclear plan
Modern Day Options Trading For Beginners! (Ad)pixel
Factory or farm? Oregon may alter land use for chipmakers
Travel disruption hits Germany on eve of transport strike
My No. 1 dividend stock for a LIFETIME of income. (Ad)
Adele extends Las Vegas residency, plans concert film
Berlin climate proposal fails to get enough yes votes to win
My No. 1 dividend stock for a LIFETIME of income. (Ad)
Turkmenistan votes for new, opposition-free parliament
Technical issues at Lufthansa cause delays in Frankfurt
S&P 500   3,970.99
DOW   32,237.53
QQQ   310.89
Ukraine demands emergency UN meeting over Putin nuclear plan
Modern Day Options Trading For Beginners! (Ad)pixel
Factory or farm? Oregon may alter land use for chipmakers
Travel disruption hits Germany on eve of transport strike
My No. 1 dividend stock for a LIFETIME of income. (Ad)
Adele extends Las Vegas residency, plans concert film
Berlin climate proposal fails to get enough yes votes to win
My No. 1 dividend stock for a LIFETIME of income. (Ad)
Turkmenistan votes for new, opposition-free parliament
Technical issues at Lufthansa cause delays in Frankfurt
NASDAQ:AKTX

Akari Therapeutics - AKTX Stock Forecast, Price & News

$0.25
-0.01 (-2.07%)
(As of 03/24/2023 08:50 PM ET)
Add
Compare
Today's Range
$0.24
$0.27
50-Day Range
$0.23
$0.54
52-Week Range
$0.22
$1.61
Volume
108,500 shs
Average Volume
131,551 shs
Market Capitalization
$18.65 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$2.75

Akari Therapeutics MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
997.8% Upside
$2.75 Price Target
Short Interest
Healthy
0.12% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.94mentions of Akari Therapeutics in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
N/A

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.99 out of 5 stars

Medical Sector

647th out of 995 stocks

Pharmaceutical Preparations Industry

312th out of 482 stocks


AKTX stock logo

About Akari Therapeutics (NASDAQ:AKTX) Stock

Akari Therapeutics Plc is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics to treat orphan autoimmune and inflammatory diseases. Its lead product candidate, Nomacopan, is a second-generation complement inhibitor. The company was founded on October 7, 2004 and is headquartered in London, the United Kingdom.

Receive AKTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Akari Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

AKTX Stock News Headlines

Akari Therapeutics (NASDAQ:AKTX) Now Covered by StockNews.com
AKTX Akari Therapeutics, Plc
[BREAKING] New "Living Missile" to Replace Nuclear Missiles
CBS News Reports: "It's an entirely new type of weapon." The New York Times Reports: "No existing defense can stop it." And one small company is building them for the Pentagon!
BREAKING: Tiny biotech successfully treats blindness
There's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.
Akari Therapeutics Plc - ADR
Short Volatility Alert: AKARI THERAPEUTICS
See More Headlines
Receive AKTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Akari Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

AKTX Company Calendar

Last Earnings
3/31/2020
Today
3/26/2023
Next Earnings (Estimated)
5/15/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:AKTX
Employees
9
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$2.75
High Stock Price Forecast
$4.00
Low Stock Price Forecast
$1.50
Forecasted Upside/Downside
+997.8%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-17,420,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$0.11 per share

Miscellaneous

Free Float
28,440,000
Market Cap
$18.65 million
Optionable
Not Optionable
Beta
1.38

Key Executives

  • Rachelle Jacques
    President, Chief Executive Officer & Director
  • Melissa Bradford-Klug
    Chief Operating Officer
  • Torsten Hombeck
    Chief Financial & Accounting Officer
  • Miles Nunn
    Chief Scientific Officer
  • John F. Neylan
    Chief Medical Officer & Executive Vice President













AKTX Stock - Frequently Asked Questions

Should I buy or sell Akari Therapeutics stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Akari Therapeutics in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" AKTX shares.
View AKTX analyst ratings
or view top-rated stocks.

What is Akari Therapeutics' stock price forecast for 2023?

2 Wall Street research analysts have issued 12 month price objectives for Akari Therapeutics' shares. Their AKTX share price forecasts range from $1.50 to $4.00. On average, they predict the company's share price to reach $2.75 in the next year. This suggests a possible upside of 997.8% from the stock's current price.
View analysts price targets for AKTX
or view top-rated stocks among Wall Street analysts.

How have AKTX shares performed in 2023?

Akari Therapeutics' stock was trading at $0.4699 at the start of the year. Since then, AKTX shares have decreased by 46.7% and is now trading at $0.2505.
View the best growth stocks for 2023 here
.

When is Akari Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 15th 2023.
View our AKTX earnings forecast
.

How were Akari Therapeutics' earnings last quarter?

Akari Therapeutics, Plc (NASDAQ:AKTX) released its quarterly earnings data on Tuesday, March, 31st. The biopharmaceutical company reported ($0.39) EPS for the quarter, missing analysts' consensus estimates of ($0.14) by $0.25.

What other stocks do shareholders of Akari Therapeutics own?
What is Akari Therapeutics' stock symbol?

Akari Therapeutics trades on the NASDAQ under the ticker symbol "AKTX."

Who are Akari Therapeutics' major shareholders?

Akari Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional investors include Armistice Capital LLC (4.66%).
View institutional ownership trends
.

How do I buy shares of Akari Therapeutics?

Shares of AKTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Akari Therapeutics' stock price today?

One share of AKTX stock can currently be purchased for approximately $0.25.

How much money does Akari Therapeutics make?

Akari Therapeutics (NASDAQ:AKTX) has a market capitalization of $18.65 million. The biopharmaceutical company earns $-17,420,000.00 in net income (profit) each year or ($0.35) on an earnings per share basis.

How can I contact Akari Therapeutics?

Akari Therapeutics' mailing address is 75/76 WIMPOLE STREET, LONDON X0, W1G 9RT. The official website for the company is www.akaritx.com. The biopharmaceutical company can be reached via phone at 442080040261, via email at info@akaritx.com, or via fax at 646-843-9352.

This page (NASDAQ:AKTX) was last updated on 3/27/2023 by MarketBeat.com Staff